Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PMCB - PharmaCyte Biotech, Inc.

IEX Last Trade
1.57
-0.020   -1.274%

Share volume: 2
Last Updated: Thu 26 Dec 2024 08:28:52 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%
$1.59
-0.02
-1.26%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
0   0%
1 Month
-7.51%
3 Months
-11.11%
6 Months
-20.40%
1 Year
-30.74%
2 Year
-45.21%
Key data
Stock price
$1.57
P/E Ratio 
0.00
DAY RANGE
$1.59 - $1.59
EPS 
$0.00
52 WEEK RANGE
$1.55 - $2.58
52 WEEK CHANGE
-$29.20
MARKET CAP 
11.795 M
YIELD 
N/A
SHARES OUTSTANDING 
7.709 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.68
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$7,791
AVERAGE 30 VOLUME 
$12,712
Company detail
CEO: Joshua N. Silverman
Region: US
Website: pharmacyte.com
Employees: 4
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

PharmaCyte Biotech, Inc. focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer.

Recent news